Guangxi Yinhe Group Co., Ltd. entered into an agreement to acquire 60% stake in Jiangsu Decon Bio-Sci-Technology Co., Ltd. from Galaxy Biomedical Investment Co., Ltd. (SZSE:000806) for CNY 160 million on August 24, 2017. For the year ended December 31, 2016, Jiangsu Decon Bio-Sci-Technology Co., Ltd. reported total assets of CNY 45.1 million, net assets of CNY 36.4 million, revenue of CNY 36.2 million, operating profit of CNY 14.7 million, and net profit of CNY 13.01 million. The transaction is subject to shareholders’ approval of Galaxy Biomedical Investment Co., Ltd. The transaction has been approved by the 3rd session of 9th directorate of Galaxy Biomedical Investment Co., Ltd. Guangxi Yinhe Group Co., Ltd. cancelled the acquisition of 60% stake in Jiangsu Decon Bio-Sci-Technology Co., Ltd. from Galaxy Biomedical Investment Co., Ltd. (SZSE:000806) on August 24, 2018.